Carlo Russo
Technik-/Wissenschafts-/F&E-Leiter bei GENENTA SCIENCE S.P.A.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Carlo Russo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GENENTA SCIENCE S.P.A. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2021 | - |
Karriereverlauf von Carlo Russo
Ehemalige bekannte Positionen von Carlo Russo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.05.2016 | 01.07.2016 |
VaxInnate Corp.
 VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Vorstandsvorsitzender | - | - |
| Präsident | - | - |
Ausbildung von Carlo Russo
| University of Genoa | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Italien | 3 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Chief Executive Officer | 1 |
| President | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| GENENTA SCIENCE S.P.A. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
VaxInnate Corp.
VaxInnate Corp. Pharmaceuticals: MajorHealth Technology VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ. | Health Technology |
- Börse
- Insiders
- Carlo Russo
- Erfahrung
